Kymera Therapeutics, Inc. (KYMR)

85.68 -4.00 (-4.46%) USD  |  NASDAQ  |  Dec 15, 16:00
85.64 -0.04 (-0.05%) Pre-Market: 08:11
More

Kymera Therapeutics Research and Development Expense (Quarterly): 71.94M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for KYMR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 1.334B
Regeneron Pharmaceuticals, Inc. 1.338B
Sanofi --
Cytokinetics, Inc. 96.55M
TG Therapeutics, Inc. 40.88M